Table 3.
Quantitative risk assessments for adventitious agents: Worst case residual virus content in a trivalent vaccine dose.
| Virus type/group | log10 human infectious dose/vaccine dosea |
|---|---|
| Influenza vaccine virus | −16.0 |
| Adenovirus | −8.1 |
| Herpes simplex virus | −9.7 |
| Other human Herpesviruses | −10.1 |
| Parainfluenzavirus | −14.0 |
| Respiratory syncytial virus | −14.9 |
| Metapneumovirus | −9.9 |
| Mumps/Measles virus | −9.9 |
| Coronavirus | −14.1 |
| Rhinovirus | −8.8 |
| Enterovirus | −8.1 |
| Polyomavirus (JC/BK virus) | −7.7 |
| Hepatitis B, C, G viruses | −11.0 |
| Human Retroviruses | −11.8 |
| Mammalian Orthoreovirus | −8.3 |
| Chlamydia | −13.4 |
| Mycoplasma | −13.1 |
a
The values for potential avian and other animal-derived contaminating viruses, which are not known to infect humans, range from −7.1 (avian polyomavirus) to −13.8 (avian retrovirus).